Selective chemoprophylaxis guided by multifactorial analysis in superficial bladder cancer.
One hundred and five patients with superficial bladder cancer (60 primary and 45 recurrent tumors) entered a prospective chemoprophylaxis trial after transurethral resection of the tumor. The drug for chemoprophylaxis was chosen by a computer which received the tumor data and analyzed them through a previous program of recurrence risk factors (multivariant analysis). In comparison with the aleatory selection of the drug, this statistical computerized choice has diminished the recurrence index (from 8 to 3) and increased the interval free of disease (from 70 to 83.5 months) in this group of patients.
Vera-Donoso
C D
CD
Service of Urology, La Fe Hospital, Valencia, Spain.
Llopis
B
B
Oliver
F
F
Gallego
J
J
Ruiz
J
J
Vidal
J
J
Jiménez Cruz
J F
JF
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use; D004360:Drug Therapy, Computer-Assisted; D006801:Humans; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011446:Prospective Studies; D012307:Risk Factors; D013813:Therapy, Computer-Assisted; D013852:Thiotepa / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
D000970:Antineoplastic Agents; D004317:Doxorubicin; D013852:Thiotepa; D002945:Cisplatin